{
    "clinical_study": {
        "@rank": "158161", 
        "arm_group": {
            "arm_group_label": "FOLFIRI", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1;  followed by  5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion."
        }, 
        "brief_summary": {
            "textblock": "This phase \u2161 study was designed to evaluate the efficacy and safety of FOLFIRI as\n      second-line treatment for metastatic esophageal carcinoma."
        }, 
        "brief_title": "FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Esophageal Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Esophageal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Although there are no standard second-line treatment for metastatic esophageal carcinoma,\n      some studies have showed that irinotecan, fluorouracil may be effective in treating patients\n      with metastatic esophageal carcinoma after failure of first-line treatment. Since\n      irinotecan, fluorouracil, and leucovorin work in different ways to stop the growth of tumor.\n      Giving more than one drug may be more effective. In this phase \u2161 trial, the investigator\n      would like to observe the efficacy and safety of FOLFIRI(Irinotecan/5-FU/leucovorin ) as\n      second-line treatment for metastatic esophageal carcinoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients have provided a signed Informed Consent Form\n\n          -  Karnofsky score \u226570\n\n          -  Age: 18-75 years old\n\n          -  Histologically confirmed diagnosis of advanced esophageal carcinoma\n\n          -  Patients have Received and progressed on first-line treatment, and not received\n             CPT-11 or Fluoropyrimidine based palliative chemotherapy\n\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1\n             criteria\n\n          -  Life expectancy \u2265 3 months\n\n          -  Patient has adequate bone marrow and organ function\n\n               -  Absolute Neutrophil Count (ANC) \u2265 1.5 x 109/L\n\n               -  Platelets \u2265 75 x 109/L\n\n               -  Hemoglobin \u2265 9.0 g/dL\n\n          -  Patient has adequate liver function\n\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\n                  liver metastasis)\n\n               -  Serum bilirubin \u2264 2 x ULN\n\n          -  Creatinine \u2264 1.5 times ULN\n\n          -  Good compliance\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women\n\n          -  Brain metastasis or only with bone metastasis.\n\n          -  Patients with severe infection or active peptic ulcer which need treatment\n\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\n             cardiac, liver, renal diseases\n\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\n             situ\n\n          -  Psychiatric illness that would prevent the patient from giving informed consent\n\n          -  Patient is concurrently using other approved or investigational antineoplastic agent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02023593", 
            "org_study_id": "FOLFIRI-29"
        }, 
        "intervention": {
            "arm_group_label": "FOLFIRI", 
            "description": "Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1;  followed by  5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.", 
            "intervention_name": "FOLFIRI", 
            "intervention_type": "Drug", 
            "other_name": [
                "Irinotecan", 
                "Leucovorin", 
                "5-Fluorouracil"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Irinotecan", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 23, 2013", 
        "location": {
            "contact": {
                "email": "liyh@sysucc.org.cn", 
                "last_name": "Li Yuhong, Ph D"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University Cancer Center"
            }, 
            "investigator": {
                "last_name": "Li Yuhong, Ph D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase \u2161 Study of FOLFIRI as Second-Line Chemotherapy for Metastatic Esophageal Carcinoma", 
        "overall_contact": {
            "email": "liyh@sysucc.org.cn", 
            "last_name": "Li Yuhong, Ph D"
        }, 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "Li Yuhong, Ph D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease control rate", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02023593"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Yuhong Li", 
            "investigator_title": "MD,Ph D", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From the date of first drug administration until the date of death, assessed up to 60months"
            }, 
            {
                "description": "Safety data will be assessed at each study visiting using NCI CTCAE version 3.0", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Each follow up visit, assessed up to 24 weeks"
            }, 
            {
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "From the  date of first drug administration  until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhong Li", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}